Dianne Pulte

United States Food and Drug Administration — United States

Medicine · Health Sciences

33h-index4.7kcitations134works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(31), Acute Myeloid Leukemia Research(31), Acute Lymphoblastic Leukemia research(30), Chronic Lymphocytic Leukemia Research(30), Chronic Myeloid Leukemia Treatments(24)

Publications134 total

Real‐World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and <i>TP53</i> Gene Mutation or 17p Deletion
American Journal of Hematology·2025Open Access
Chronic myelomonocytic leukemia: Clinical outcomes from clinical trials submitted to the FDA over the past 25 years
Blood·2025Open Access
Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States
Blood·2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia
Journal of Clinical Oncology·2025
Supplementary Table S3 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an &lt;i&gt;IDH1&lt;/i&gt; Mutation
2025Open Access
Supplementary Table S1 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an &lt;i&gt;IDH1&lt;/i&gt; Mutation
2025Open Access
Supplementary Table S2 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an &lt;i&gt;IDH1&lt;/i&gt; Mutation
2025Open Access
Data from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an &lt;i&gt;IDH1&lt;/i&gt; Mutation
2025Open Access
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an <i>IDH1</i> Mutation
Clinical Cancer Research·2025· 1 citedOpen Access
Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses
Blood·2024· 1 cited
FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome
Blood·2024Open Access
FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity
Blood·2024Open Access
Overcoming underestimation of the association of excess weight with pancreatic cancer due to prediagnostic weight loss: Umbrella review of systematic reviews, meta‐analyses, and pooled‐analyses
Obesity Reviews·2024· 6 citedOpen Access
Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia
Blood·2024· 11 cited
Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)
Blood·2023· 1 citedOpen Access
The underestimated impact of excess body weight on colorectal cancer risk: Evidence from the UK Biobank cohort
British Journal of Cancer·2023· 19 citedOpen Access
Data from FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a &lt;i&gt;FLT3&lt;/i&gt; Mutation
2023Open Access
Data from FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a &lt;i&gt;FLT3&lt;/i&gt; Mutation
2023Open Access
Supplementary Data from FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a &lt;i&gt;FLT3&lt;/i&gt; Mutation
2023Open Access
Supplementary Data from FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a &lt;i&gt;FLT3&lt;/i&gt; Mutation
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Hermann Brenner(34), Ádám Gondos(17), Lina Jansen(16), Bernd Holleczek(7), Alexander Katalinic(6), Maria Theresa Redaniel(6), Felipe A. Castro(5), Richard Pazdur(5), Mona Jeffreys(4), M. Johan Broekman(4), Kim E. Olson(4), Aaron J. Marcus(4), Katharina Emrich(4), Ann T. Farrell(4), Benjamin Barnes(3), Meike Ressing(3), Joan H.F. Drosopoulos(3), Naziba Islam(3), Kelly J. Norsworthy(3), Kirsten B. Goldberg(3)